2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 17, 2008, Pages 4833-4837

  Berger, Richard ^a   Zhu, Cheng ^a   Hansen, Alexa R ^a   Harper, Bart ^a   Chen, Zhesheng ^a   Holt, Tom G ^a   Hubert, James ^a   Lee, Susan J ^a   Pan, Jie ^a   Qian, Su ^a   Reitman, Marc L ^a   Strack, Alison M ^a   Weingarth, Drew T ^a   Wolff, Michael ^a   MacNeil, Douglas J ^a   Weber, Ann E ^a   Edmondson, Scott D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CCK1R; Cholecystokinin; Imidazole carboxamides; Obesity

Indexed keywords

CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; IMIDAZOLECARBOXAMIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ASSAY; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; FOOD INTAKE; MOUSE; NONHUMAN; OBESITY; ST?UCTURE ACTIVITY RELATION;

ANIMALS; ANTI-OBESITY AGENTS; BENZODIAZEPINES; HUMANS; INDOLES; METHYLAMINES; MICE; OBESITY; PIPERAZINES; RECEPTOR, CHOLECYSTOKININ A; RECEPTORS, CHOLECYSTOKININ; THIAZOLES;

EID: 49849106067     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.083     Document Type: Article

References (37)

1. Department of Health and Human Services, Center for Disease Control and Prevention: 'Overweight and Obesity' http://www.cdc.gov/nccdphp/dnpa/obesity/index.htm (2007).
2. Balkau B., Deanfield J.E., Després J.-P., Bassand J.-P., Fox K.A.A., Smith S.C., Barter P., Tan C.-E., Van Gaal L., Wittchen H.-U., Massien C., and Haffner S.M. Circulation 116 (2007) 1942
3. Adams K.F., Schatzkin A., Harris T.B., Kipnis V., Mouw T., Ballard-Barbash R., Hollenbeck A., and Leitzmann M.F. N. Engl. J. Med. 335 (2006) 763
4. McTigue K., Larson J.C., Valoski A., Burke G., Kotchen J., Lewis C.E., Stefanick M.L., Van Horn L., and Kuller L. JAMA 296 (2006) 79
5. Katzmarzyk P.T., Janssen I., and Ardern C.I. Obes. Rev. 4 (2003) 257
6. Venkat Narayan K.M., Boyle J.P., Thompson T.J., Sorensen S.W., and Williamson D.F. JAMA 290 (2003)
7. Lieverse R.J., Jansen J.B.M.L., Masclee A.A.M., and Lamers C.B.H.W. Ann. NY Acad. Sci. 713 (1994) 268
8. Liddle R.A., Goldfine I.D., Rosen M.S., Taplitz R.A., and Williams J.A. J. Clin. Invest. 75 (1985) 1144
9. Kissileff H.R., Pi-Sunyer F.X., Thornton J., and Smith G.P. Am. J. Clin. Nutr. 34 (1981) 154
10. Chandra R., and Little T.J. Curr. Opin. Endocrinol. Diabetes Obes. 14 (2007) 63
11. Dufresne M., Seva C., and Fourmy D. Physiol. Rev. 86 (2006) 805
12. Moran T.H., and Kinzig K.P. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G183
13. Little T.J., Horowitz M., and Feinle-Bisset C. Obes. Rev. 6 (2005) 297
14. Cox J.E., and Randich A. Brain Res. 776 (1997) 189
15. Moran T.H., Norgren R., Crosby R.J., and McHugh P.R. Brain Res. 526 (1990) 95
16. Gibbs J., Young R.C., and Smith G.P. J. Comp. Physiol. Psychol. 84 (1973) 488
17. Gibbs J., Falasco J.D., and McHugh P.R.. Am. J. Physiol. 230 (1976) 12
18. Noble F., Wank S.A., Crawley J.N., Bradwejn J., Serogy K.B., Hamon M., and Roques B.P. Pharmacol. Rev. 51 (1999) 745
19. de Weerth A., Pisegna J.R., Huppi K., and Wank S.A. Biochem. Biophys. Res. Commun. 194 (1993) 811
20. Chen D., Zhao C.M., Hakanson R., Samuelson L.C., Rehfeld J.F., and Friis-Hansen L. Gastroenterology 126 (2004) 476
21. Wank S.A., Pisegna J.R., and de Weerth A. Ann. NY Acad. Sci. 713 (1994) 49
22. Wank S.A. Am. J. Physiol. 274 (1998) G607
23. García-López M.T., González-Muñiz R., Martín-Martínez M., and Herranz R. Curr. Top. Med. Chem. 7 (2007) 1180
24. Szewczyk J.R., and Laudeman C. Curr. Top. Med. Chem. 3 (2003) 837
25. Bignon E., Bachy A., Boigegrain R., Brodin R., Cottineau M., Gully D., Herbert J.-M., Keane P., Labie C., Molimard J.-C., Olliero D., Oury-Donat F., Petereau C., Prabonnaud V., Rockstroh M.-P., Schaeffer P., Servant O., Thurneyssen O., Soubrié P., Pascal M., Maffrand J.-P., and Le Fur G. JPET 289 (1999) 742
26. Castillo E.J., Delgado-Aros S., Camilleri M., Burton D., Stephens D., O'Connor-Semmes R., Walker A., Shachoy-Clark A., and Zinsmeister A.R.. Am. J. Physiol. Gastrointest. Liver Physiol. 287 (2004) G363
27. Jordan J., Greenway F.L., Leiter L.A., Li Z., Jacobson P., Murphy K., Hill J., Kler L., and Aftring R.P. Clin. Pharmacol. Ther. 83 (2008) 281
28. Zhu C., Hansen A.R., Bateman T., Chen Z., Holt T.G., Hubert J.A., Karanam B.V., Lee S.J., Pan J., Qian S., Reddy V.B.G., Reitman M.L., Strack A.M., Tong V., Weber A., Weingarth D.T., Wolff M.S., MacNeil D.J., Weber A.E., Duffy J.L., and Edmondson S.D. Bioorg. Med. Chem. Lett. 18 (2008) 4393
29. Berger, R.; Edmondson, S. E.; Hansen, A. R.; Zhu, C. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators. WO2007120688, 2007.
30. Ueki H., Ellis T.K., Martin C.H., Boettiger T.U., Bolene S.B., and Soloshonok V.A. J. Org. Chem. 68 (2003) 7104
31. Old D.W., Wolfe J.P., and Buchwald S.L. J. Am. Chem. Soc. 120 (1998) 9722
32. 50 values are human IP3 (NFAT) agonist data except in Table 4 which are mouse CCK1R IP3 data. CCK1R % activations are expressed as the % of activation relative to CCK-8. Additional assay protocols are available in the Supporting information.
33. 50s are an average of ≥3 experiments with standard deviations <75% of the average. Additional assay protocols are given in the Supporting information.
34. For a reference describing the ONFI studies in more detail: Lee, S. J.; Hubert, J. A.; Edmondson, S. D.; Zhu, C.; Hansen, A. R.; Wolff, M. S.; Holt, T. G.; Karanam, B. V.; Kumar, S.; Qian, S.; Weingarth, D. T.; Pan, J.; Weber, A. E.; MacIntyre, D. E.; Strack, A. M.; MacNeil, D. J., manuscript in preparation.
35. Kopin A.S., Mathes W.F., McBride E.W., Nguyen M., Al-Haider W., Schmitz F., Bonner-Weir S., Kanarek R., and Beinborn M. J. Clin. Invest. 103 (1999) 383
36. -/- mice. Subsequent manuscripts describing the in vivo characteristics of selective CCK1R agonists are currently in preparation.
37. Sugg E.E., Birkemo L., Gan L.L., and Tippin T.K. Pharm. Biotechnol. 11 (1998) 507